Plain-English translation of NCT00571389 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study that collects blood samples through a process called leukapheresis—a special procedure that separates specific immune cells from your blood and returns the rest back to you. Researchers will use these cells to develop and test a new laboratory device designed to grow, study, and store immune cells. The goal is to create better tools for future cancer research and treatment development.
Scientists believe that certain immune cells in the blood—particularly T cells—hold promise for fighting cancer. This study exists to develop the technology and methods needed to reliably collect, grow, and study these cells in the laboratory, which could eventually lead to new cancer treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify and consent to participate, you will undergo a leukapheresis procedure—a process where blood is drawn from one arm, passed through a machine that separates out specific immune cells, and the remaining blood is returned through the other arm. This typically takes 2–3 hours. Your blood samples and the cells collected will be processed in the laboratory and stored for research use. Depending on which group you join (cancer patient, healthy volunteer, or COVID-19 donor), you may provide samples once or multiple times, and your participation may involve basic health screening and blood tests to ensure you are safe for the collection procedure.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Sponsor
BioCytics, Inc.
Enrollment target
~1,500 participants
Started
November 2007
Primary completion
February 2030
Age range
5 Years and older
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.